The Proactive Patient: Long-Term Care Insurance Discrimination Risks of Alzheimer's Disease Biomarkers

The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics
Jalayne J AriasJason Karlawish

Abstract

Previously diagnosed by symptoms alone, Alzheimer's disease is now also defined by measures of amyloid and tau, referred to as "biomarkers." Biomarkers are detectible up to twenty years before symptoms present and open the door to predicting the risk of Alzheimer's disease. While these biomarkers provide information that can help individuals and families plan for long-term care services and supports, insurers could also use this information to discriminate against those who are more likely to need such services. In this article, we evaluate whether state laws prohibit long-term care insurers from making discriminatory or unfair underwriting and coverage decisions based Alzheimer's disease biomarkers status. We report data demonstrating that current state laws do not provide meaningful protections from discrimination by long-term care insurers based on biomarker information.

References

Mar 21, 2008·Journal of Advanced Nursing·Satu Elo, Helvi Kyngäs
Jan 6, 2010·Health Affairs·Donald H TaylorRobert C Green
May 19, 2010·Evaluation Review·Charles TremperAlexander C Wagenaar
Mar 26, 2016·Alzheimer's & Dementia : the Journal of the Alzheimer's Association·Bruno DuboisUNKNOWN Proceedings of the Meeting of the International Working Group (IWG) and the American Alzheimer's Association on “The Preclin
Mar 30, 2017·Expert Review of Pharmacoeconomics & Outcomes Research·Arijita DebKim Innes
May 12, 2017·Gerontology & Geriatric Medicine·James D Holt
Oct 27, 2017·Alzheimer's & Dementia : Translational Research & Clinical Interventions·Jeffrey CummingsKate Zhong

❮ Previous
Next ❯

Citations

Apr 18, 2019·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Emily A Largent
Dec 4, 2019·Topics in Magnetic Resonance Imaging : TMRI·Luke W BonhamJennifer S Yokoyama
Aug 28, 2018·The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics·Allison K Hoffman
Jan 5, 2021·JAMA Neurology·Emily A LargentJason Karlawish
Jan 10, 2021·Genetics in Medicine : Official Journal of the American College of Medical Genetics·Jalayne J AriasKathryn A Phillips
Oct 28, 2021·AJOB Neuroscience·Ana M TylerJalayne J Arias

❮ Previous
Next ❯

Software Mentioned

GINA
RedCap

Related Concepts

Related Feeds

Alzheimer's Disease: APP

Amyloid precursor protein (APP) proteolysis is critical for the development of Alzheimer's disease, a neurodegenerative disease associated with accumulation of amyloid plaques in the brain. Here is the latest research on APP and Alzheimer's disease.

Alzheimer's Disease: Tau & TDP-43

Alzheimer's disease is a neurodegenerative disease. This feed focuses on the underlying role of tau proteins and TAR DNA-binding protein 43, as well as other genetic factors, in Alzheimer's disease.

Alzheimer's Disease: Amyloid Beta

Alzheimer's disease is a neurodegenerative disease associated with the accumulation of amyloid plaques in the brain; these plaques are comprised of amyloid beta deposits. Here is the latest research in this field.

Related Papers

Transactions of the Association of Life Insurance Medical Directors of America
F J Newirth
Genetics in Medicine : Official Journal of the American College of Medical Genetics
Mark A Hall, S S Rich
© 2022 Meta ULC. All rights reserved